Anti-DHX9 and Anti-SCO1 antibodies in research on the impact of histone density on cancer biology
September 2022 (The FIRC Institute of Molecular Oncology (IFOM), Milan, Italy)
The histone landscape in humans is complex: while there is only one histone H4 protein, diverse variants exist for H2A, H2B, and H3.
In addition, aberrant histone levels have been reported for several cancer cell lines.
Our Triple A Polyclonals anti-DHX9 (HPA028050) and anti-SCO1 (HPA021579) were used in western blot in a study aiming to investigate the impact of histone density on cancer biology.
By using the Cancer Cell Line Encyclopedia (CCLE) project (which has characterized more than 1300 human cancer cell lines), the authors explored proteome, transcriptome, drug resistance, and epigenetic modification patterns associated with histone density across cancer cell lines, revealing links between histone density, mitochondrial proteome composition, histone hyper-acetylation, and altered cancer drug sensitivities.
Read more: Bruhn, C., Bastianello, G. & Foiani, M. Cancer cell histone density links global histone acetylation, mitochondrial proteome and histone acetylase inhibitor sensitivity. Commun Biol 5, 882 (2022).
Download our free white paper and discover our primary antibodies targeting histones. https://www.atlasantibodies.com/globalassets/white-papers/024-histones-white-paper.pdf